Meta-analysis Shows Reduced 1-Year Mortality with TAVR in Low-Risk Severe AS Patients

Mandana Chitsazan, M.D.
By Mandana Chitsazan, M.D. on

In a meta-analysis of RCTs comparing TAVR (Transcatheter Aortic Valve Replacement) versus SAVR (Surgical Aortic Valve Replacement) in low-risk patients with severe AS, TAVR was associated with a significantly lower risk of all-cause and cardiovascular mortality at 1 year follow up. The study conducted by Kolte was recently published in the Journal of American College of Cardiology.

Several recent studies demonstrated similar outcomes with TAVR vs. SAVR in low-risk patients with severe AS. The US Food and Drug Administration has recently approved the expanded indication for the self-expanded Evolut series (Medtronic) and the balloon-expandable Sapien 3 and Sapien Ultra (Edwards Lifesciences) transcatheter heart valves for the treatment of low-risk patients with severe aortic stenosis.  The expanded indication was based on the results from the Evolut Low-Risk trial. Although these recent studies consistently showed at least comparable outcomes of TAVR and SAVR, the possible superiority of TAVR over SAVR have significant clinical implication. In this meta-analysis, the investigators aimed to compare TAVR versus SAVR in low-risk patients.

Four RCTs (one being a post hoc analysis of an RCT) were included in the final analysis. Three studies used self-expanding valves (NOTION, SURTAVI, and Evolut Low Risk) and one used balloon-expandable valves (PARTNERS 3). Data from 2,887 patients (1,497 TAVR arm and 1,390 SAVR arm) were used in the analysis. Among 1,497 patients in the TAVR arm, self-expanding valves were used in 66.9% of patients and 33.1% had a balloon-expandable valve. The primary outcome was all-cause mortality. Secondary outcomes included cardiovascular death, stroke, myocardial infarction (MI), valve/heart failure rehospitalization, new/worsening atrial fibrillation, permanent pacemaker (PPM) implantation, major vascular complications, life-threatening/disabling bleeding, acute kidney injury (AKI) stage 2/3, endocarditis, aortic valve reintervention, moderate/severe paravalvular leak (PVL), and New York Heart Association (NYHA) functional class II. Outcomes assessed at 1-year follow-up were included in the meta-analysis.

In low-risk patients with severe AS, TAVR was associated with significantly decreased risk of all-cause mortality at 1 year compared with SAVR (2.1% vs. 3.5%; RR: 0.61; 95% CI: 0.39, 0.96, p= 0.03). Considering the secondary outcomes, TAVR was associated with a significantly lower risk of cardiovascular death (1.6% vs. 2.9%; RR: 0.55; 95% CI: 0.33, 0.90; p =0.02; with no statistically significant differences in the risk of stroke, MI or valve/heart failure rehospitalization. Rates of new/worsening atrial fibrillation, life-threatening/disabling bleeding, and AKI stage 2/3 were significantly lower in the TAVR arm, whereas TAVR was associated with significantly higher rates of PPM implantation and moderate/severe PVL.

“Our study establishes a clear and robust survival advantage with TAVR over SAVR in low-risk patients. At 1-year, rates of all-cause and cardiovascular death were 40% and 45% lower, respectively, with TAVR. Our findings reiterate the superiority of TAVR over SAVR in low-risk patients with AS and suggest that TAVR should be the preferred option for such patients in whom a bioprosthetic valve is being considered. Further data are needed to determine whether these observations hold true beyond 1-year ”.- Dr. Sammy Elmariah, the corresponding author, told Cardiology Now News.

With Respect to safety, TAVR and SAVR had comparable rates of major vascular complications (3.6% vs. 2.4%; RR: 1.66; 95%CI: 0.89 to 3.11; p= 0.11), endocarditis (0.4% vs. 0.6%; RR: 0.73; 95% CI: 0.24 to 2.20; p=0.58), and aortic valve reintervention (1.1% vs. 0.6%; RR, 0.75; 95% CI, 0.67 to 4.59; p= 0.25).

Several caveats should be considered when interpreting the results. First, study-level data were used for the meta-analysis, rather than patient-level data. To account for the difference in follow-up duration, the 1-year outcome for the NOTION trial was derived from the 2- and 5-year rates. Third, for the Evolut Low Risk trial, the true incidence was not available and the frequency of events was estimated. Last, the influence of covariates such as age and valve type could not be determined due to the limited number of studies included.



Leave a Reply